Weightmans advises on sale of Strategic North
Weightmans has advised the shareholders of Strategic North on its sale to Prescient Healthcare Group.
National law firm Weightmans has advised the shareholders of Strategic North, a global healthcare research and commercial strategy consultancy, on its sale to Prescient Healthcare Group, a biopharma product and portfolio strategy firm.
Founded in 2010, Strategic North employs 70 executives out of its offices in the UK. The firm supports Global Marketing, New Product Planning and Insight functions in the development of brand value propositions, positioning and messaging, and the rollout of global strategy to affiliates.
Commenting on the successful deal, Sarah said: “Our excellent cross-practice, cross-office team was delighted to have been able to advise the shareholders of Strategic North on this transaction. Strategic North has built an impressive business and Weightmans is proud to have supported the company and its shareholders over the last 10 years and throughout this transaction. Weightmans is excited to watch Strategic North continue to grow and drive innovation in its services in partnership with Prescient.”
Steve Padgett, Co-Founder and Managing Director at Strategic North, said, “We are hugely excited to be joining the Prescient team. Our vision has always been about providing our clients with seamlessly integrated, best-in-class specialist skills and this partnership enables us to do this in an even bigger and better way. Our core objectives for 2022 will be to effectively integrate our respective teams and cultures, expand the Strategic North capability in the US and further differentiate our core service lines by leveraging our combined capabilities.”
The Weightmans team included Kerry Waters, Employment Principal Associate, Tom Trowhill, Commercial Principal Associate, Fran Hillyard, Corporate Associate, Jack Rayson, Real Estate Associate, and Michelle Hall, Corporate Paralegal.
Prescient, which was founded in 2007, has offices in eight cities spanning the US, Europe and Asia, and partners with 23 of the top 25 biopharmaceutical companies in the world. It specialises in dynamic decision support and product and portfolio strategy.